CureVac Receives Grants for Three Patents Regarding Intratumoral Application of RNA
13. Juni 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, June 13, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced that it received a...
Exklusive Forschungskooperation zwischen CureVac und dem Schepens Eye Research Institute der Harvard Medical School und deren Massachusetts Eye and Ear Infirmary zur Erforschung mRNA-basierter Arzneimittelkandidaten für die Behandlung von Augenerkrankungen
20. Mai 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Deutschland / BOSTON, MA, May 20, 2019 (GLOBE NEWSWIRE) -- Das biopharmazeutische Unternehmen CureVac AG, Pionier im Bereich mRNA-basierter Impfstoffe und Therapeutika, gab heute den...
CureVac Enters into an Exclusive Sponsored Research Agreement for Discovery Research in mRNA-based Eye Therapy Candidates with the Schepens Eye Research Institute, Harvard Medical School and the Massachusetts Eye and Ear Infirmary
20. Mai 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, May 20, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced it has entered into a...
CureVac erhält Patent für die Kombination mRNA-basierter Impfstoffe und Anti-PD-L1-Antikörper
16. April 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Deutschland / BOSTON, MA, April 16, 2019 (GLOBE NEWSWIRE) -- Das biopharmazeutische Unternehmen CureVac AG, Pionier im Bereich mRNA-basierter Impfstoffe und Therapeutika, gab heute...
CureVac Granted Patent Claiming the Combination of mRNA Vaccines with Anti-PD-L1 Antibodies
16. April 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, April 16, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced today it has been...
CureVac nimmt an bevorstehenden Investorenkonferenzen teil
09. April 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Deutschland und BOSTON, April 09, 2019 (GLOBE NEWSWIRE) -- Das biopharmazeutische Unternehmen CureVac AG, Pionier im Bereich mRNA-basierter Impfstoffe und Therapeutika, kündigte heute...
CureVac to Participate in Upcoming Investor Conferences
09. April 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, April 09, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced its...
CureVac kündigt Late-Breaking-Posterpräsentation mit neuesten Daten anlässlich der Jahreskonferenz 2019 der American Association of Cancer Research (AACR) an
21. März 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Deutschland / BOSTON, MA, March 21, 2019 (GLOBE NEWSWIRE) -- Das biopharmazeutische Unternehmen CureVac AG, Pionier im Bereich mRNA-basierter Impfstoffe und Therapeutika, kündigte die...
CureVac Announces Late-Breaking Poster Presentation at American Association of Cancer Research (AACR) Annual Meeting 2019
21. März 2019 07:00 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, March 21, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced it will present...
CEPI awards US$ 34M contract to CureVac to advance The RNA Printer™—a disruptive, transportable mRNA vaccine manufacturing platform that can rapidly combat multiple diseases
27. Februar 2019 07:30 ET
|
CureVac AG
OSLO, Norway, Feb. 27, 2019 (GLOBE NEWSWIRE) -- The Coalition for Epidemic Preparedness Innovations (CEPI) and CureVac AG, a biopharmaceutical company pioneering the field of mRNA-based vaccines,...